Tevogen Bio (NASDAQ:TVGN) Now Covered by Analysts at D. Boral Capital

D. Boral Capital began coverage on shares of Tevogen Bio (NASDAQ:TVGN) in a research note released on Tuesday morning, MarketBeat.com reports. The firm issued a buy rating and a $10.00 price objective on the stock.

Tevogen Bio Stock Performance

Shares of NASDAQ TVGN opened at $1.27 on Tuesday. The business has a fifty day moving average price of $1.35 and a 200 day moving average price of $1.15. Tevogen Bio has a 1-year low of $0.26 and a 1-year high of $8.49.

Institutional Trading of Tevogen Bio

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of Tevogen Bio by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after acquiring an additional 107,566 shares in the last quarter. HGC Investment Management Inc. acquired a new position in shares of Tevogen Bio during the third quarter worth $82,000. Northern Trust Corp increased its position in shares of Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after purchasing an additional 13,595 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Tevogen Bio in the 4th quarter worth $55,000. Finally, Barclays PLC boosted its position in shares of Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after purchasing an additional 12,847 shares in the last quarter.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.